Acurx Pharmaceuticals Inc... (ACXP)

AI Score

Unlock

0.37

-0.02 (-3.92%)

At close: Apr 17, 2025, 3:59 PM

0.39

5.02%

After-hours: Apr 17, 2025, 04:54 PM EDT

Acurx Pharmaceuticals Balance Sheet Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q1 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Mar 31, 2020
Cash & Equivalents	3.71M	5.76M	6.36M	8.92M	7.47M	7.05M	9.15M	7.18M	9.11M	10.61M	9.09M	11.08M	12.96M	14.46M	17.1M	2.63M	3.18M	-2.48M
Short-Term Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	4.97M
Long-Term Investments	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Long-Term Assets	n/a	n/a	n/a	n/a	234.94M	n/a	n/a	n/a	264.95M	n/a	50.25K	n/a	295.3M	n/a	n/a	339.48K	n/a	-2.48M
Receivables	51.13K	97.37K	51.13K	n/a	129.16K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Inventory	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Current Assets	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total Current Assets	3.86M	5.98M	6.58M	9.11M	7.71M	7.16M	9.24M	7.39M	9.38M	10.95M	9.21M	11.32M	13.25M	14.99M	17.44M	2.64M	3.22M	2.48M
Property-Plant & Equipment	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Goodwill & Intangibles	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total Long-Term Assets	n/a	n/a	n/a	n/a	234.94M	n/a	n/a	n/a	264.95M	n/a	50.25K	n/a	295.3M	n/a	n/a	339.48K	n/a	-2.48M
Total Assets	3.86M	5.98M	6.58M	9.11M	7.71M	7.16M	9.24M	7.39M	9.38M	10.95M	9.26M	11.32M	13.25M	14.99M	17.44M	2.98M	3.22M	n/a
Account Payables	n/a	n/a	10.13K	9.2K	3.81K	11.72K	12.88K	18.41K	29.54K	5.94K	5.76K	6.36K	63.37K	12.14K	97K	396.00	n/a	n/a
Deferred Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-396	n/a	n/a
Short-Term Debt	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	16.63K	16.63K	n/a
Other Current Liabilities	537.63K	3.32B	n/a	n/a	n/a	206.81K	n/a	20.39K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total Current Liabilities	3.24M	3.32B	3.15M	3.11M	3.04M	3.22M	3.02M	2.07M	2.06M	1.18M	473.88K	633.03K	843.91K	712.44K	1.92M	460.8K	472.56K	n/a
Long-Term Debt	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	49.88K	49.88K	n/a
Other Long-Term Liabilities	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Total Long-Term Liabilities	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2.06M	n/a	473.88K	n/a	n/a	n/a	n/a	49.88K	49.88K	n/a
Total Liabilities	3.24M	3.32M	3.15M	3.11M	3.04M	3.22M	3.02M	2.07M	2.06M	1.18M	473.88K	633.03K	843.91K	712.44K	1.92M	510.68K	522.43K	n/a
Total Debt	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	66.5K	66.5K	n/a
Common Stock	17.03K	16.77K	16K	15.76K	14.47K	13.01K	13.01K	11.67K	11.63K	11.59K	10.26K	10.26K	10.22K	10.13K	9.92K	17.75M	16.5M	n/a
Retained Earnings	-67.32M	-64.54M	-61.72M	-57.6M	-53.22M	-48.1M	-44.99M	-41.54M	-38.64M	-35.38M	-31.84M	-29.22M	-26.55M	-23.92M	-19.28M	-15.27M	-13.8M	n/a
Comprehensive Income	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-38.64M	-35.38M	-31.84M	-29.22M	-26.55M	-23.92M	-19.28M	-15.27M	-13.8M	819.85K
Shareholders Equity	615.12K	2.66M	3.43M	6M	4.67M	3.93M	6.22M	5.31M	7.32M	9.76M	8.79M	10.69M	12.41M	14.28M	15.52M	2.47M	2.7M	819.85K
Total Investments	n/a	5.76B	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	4.97M